Sialanar | Dose Table

Dosing table for children and adolescents with normal renal function¹

	Dose Level 1	Dose Level 2	Dose Level 3	Dose Level 4	Dose Level 5
µg glycopyrronium bromide	(~16µg/kg)	(~32µg/kg)	(~48µg/kg)	(~64µg/kg)	(~80µg/kg)
Weight (kg)	ml	ml	ml	ml	ml
13-17	0.6	1.2	1.8	2.4	3*
18-22	0.8	1.6	2.4	3.2	4*
23-27	1	2	3	4	5*
28-32	1.2	2.4	3.6	4.8	6*
33-37	1.4	2.8	4.2	5.6	6*
38-42	1.6	3.2	4.8	6*	6*
43-47	1.8	3.6	5.4	6*	6*
≥48	2	4	6*	6*	6*

*Maximum individual dose in this weight range

Dosing table for children and adolescents with mild to moderate renal impairment (eGFR <90 - ≥30 ml/min/1.73m²)¹

	Dose Level 1	Dose Level 2	Dose Level 3	Dose Level 4	Dose Level 5
µg glycopyrronium bromide	(~11µg/kg)	(~22µg/kg)	(~34µg/kg)	(~45µg/kg)	(~56µg/kg)
Weight (kg)	ml	ml	ml	ml	ml
13-17	0.4	0.8	1.2	1.7	2.1*
18-22	0.6	1.1	1.7	2.2	2.8*
23-27	0.7	1.4	2.1	2.8	3.5*
28-32	0.8	1.7	2.5	3.4	4.2*
33-37	1	2	2.9	3.9	4.2*
38-42	1.1	2.2	3.4	4.2*	4.2*
43-47	1.2	2.5	3.8	4.2*	4.2*
≥48	1.4	2.8	4.2*	4.2*	4.2*

*Maximum individual dose in this weight range

Please refer to the SmPC for full dosing information

Request a printed dosing wheel

Submit this form to request a printed dosing wheel to support you or your team:

Name

Job Title

Place Of Work

Delivery Address

Quantity Requested

By submitting this form you understand that Proveca will store your personal data to enable us to contact you following this form submission, Proveca will also retain this data to be used for marketing and promotional purposes on the basis of legitimate interest. You can unsubscribe at any time and more information is available in our privacy policy. Please check the box to confirm.

Switching Patients to Sialanar®

Guidance on switching patients from hyoscine or 1mg/5ml glycopyrronium bromide oral solutions to Sialanar^®

Switching Patients to Sialanar®

Safety

Head to this section for guidance on side effects and titration.

Safety

Clinical Evidence

Glycopyrronium has demonstrated lower rates of side effects² and treatment cessation²^,3 vs. hyoscine.

Clinical Evidence

References

Sialanar® SmPC (January 2023) https://www.medicines.org.uk/emc/product/2301 – accessed July 2023
Parr J.R, Todhunter E, Pennington L, et al. Drooling Reduction Intervention randomized trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. Arch Dis Child 2017; 1-6. Doi:10. 1136/ archdischild-2017-313763.
Reid S.M, et al. Anticholinergic medications for reducing drooling in children with developmental disability. Developmental Medicine & Child Neurology 2019; 63(3): 346-353

UK-SIA-23-0111 | August 2023

Reporting of side effects

UK
If you/your child experience(s) any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

Republic of Ireland
If you/your child experience(s) any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Adverse event should be reported, reporting forms and information can be found at: www.hpra.ie.

By reporting side effects, you can help provide more information on the safety of this medicine.

Side effects should also be reported to Proveca Limited. Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com

Dose Table

Dosing table for children and adolescents with normal renal function1

Dosing table for children and adolescents with mild to moderate renal impairment (eGFR <90 - ≥30 ml/min/1.73m2)1

Request a printed dosing wheel

Switching Patients to Sialanar®

Safety

Clinical Evidence

References

Dosing table for children and adolescents with normal renal function¹

Dosing table for children and adolescents with mild to moderate renal impairment (eGFR <90 - ≥30 ml/min/1.73m²)¹